DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
Cixutumumab is an investigational drug.
There have been 32 clinical trials for Cixutumumab. The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2009.
The most common disease conditions in clinical trials are Carcinoma, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are National Cancer Institute (NCI), Eli Lilly and Company, and ImClone LLC.
Recent Clinical Trials for Cixutumumab
|Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma||National Cancer Institute (NCI)||Phase 2|
|18F FLT Imaging Studies of Treatment Response for Lung Cancer and Thymoma||National Cancer Institute (NCI)||Phase 2|
|BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer||Eli Lilly and Company||Phase 2|